# Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.

> **NCT00343551** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 654 (—)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Aliskiren

## Key facts

- **NCT ID:** NCT00343551
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2007-01
- **Final completion:** —
- **Target enrollment:** 654 (—)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00343551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00343551, "Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00343551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*